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Abstract
Background: Exposure to NMDA glutamate antagonists during the brain growth spurt period causes widespread
neuroapoptosis in the rodent brain. This period in rodents occurs during the first two weeks after birth, and corresponds to
the third trimester of pregnancy and several years after birth in humans. The developing human brain may be exposed to
NMDA antagonists through drug-abusing mothers or through anesthesia.
Methodology/Principal Findings: We evaluated the long-term neurobehavioral effects of mice exposed to a single dose of
the NMDA antagonist, phencyclidine (PCP), or saline, on postnatal day 2 (P2) or P7, or on both P2 and P7. PCP treatment on
P2 + P7 caused more severe cognitive impairments than either single treatment. Histological examination of acute
neuroapoptosis resulting from exposure to PCP indicated that the regional pattern of degeneration induced by PCP in P2
pups was different from that in P7 pups. The extent of damage when evaluated quantitatively on P7 was greater for pups
previously treated on P2 compared to pups treated only on P7.
Conclusions: These findings signify that PCP induces different patterns of neuroapoptosis depending on the developmental
age at the time of exposure, and that exposure at two separate developmental ages causes more severe neuropathological
and neurobehavioral consequences than a single treatment.
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Introduction
Synaptogenesis, which occurs during the first two weeks after birth
in rodents, is a developmental period of heightened sensitivity to
certain classes of drugs capable of inducing widespread neuroapop-
tosis throughout the brain. N-methy-D-aspartate (NMDA) gluta-
mate receptor antagonists (e.g. ketamine, phencyclidine [PCP],
nitrous oxide) and GABAmimetics (e.g. midazolam, phenobarbital,
isoflurane) are two classes of agents that produce apoptosis during
this vulnerability period [1–4]. While there is some overlap in the
neuronal populations killed by NMDA antagonists and GABAmi-
metics, each drug class produces its own distinct damage pattern.
Ethanol, possessing both GABAmimetic and NMDA antagonistic
properties, also triggers neuroapoptosis in the developing rodent
brain [5], which appears to be a composite of the damage patterns
resulting from exposure to NMDA antagonists and GABAmimetics.
This suggests that both neurotransmitter systems are involved in
ethanol-induced apoptotic neurodegeneration.
In humans the synaptogenesis period encompasses the last
trimester of gestation and the first few years of life [6]. Because
pregnant women or infants are exposed to these classes of agents in
clinical and drug abuse settings, there is the potential that these
drugs may produce long-lasting functional deficits in vulnerable
fetuses and infants. To date, we have conducted two studies to
determine whether apoptotic neurodegeneration produced during
this period of vulnerability results in measurable cognitive
impairments. Specifically, rats treated on postnatal day 7 (P7)
with a ‘‘cocktail’’ containing both NMDA antagonists and
GABAmimetics (nitrous oxide, isoflurane and midazolam), similar
to that used in human obstetric and pediatric anesthesia, show
spatial learning and memory deficits when tested as juveniles and
as adults [3]. Consistent with these results, mice treated with
ethanol on P7 have impairments in spatial learning and memory
when tested as juveniles but show some recovery of function by
adulthood [7]. The relative contributions of NMDA antagonism
and augmentation of GABAergic activity to the cognitive deficits
in ethanol-treated mice are currently unknown. Other studies
examining effects of multiple doses of PCP (P7, 9 and 11) have
found long-term deficits in sensorimotor gating, delayed alterna-
tion and adult locomotor activity in rats [8–10] and impairments
in spatial working memory and social interaction in mice [11].
Therefore, one goal of the conducted research was to determine
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what long-term behavioral functions would be disrupted in mice
with a single exposure on P7 to PCP.
Another important determinant of neuroapoptosis in rodents is
a varying sensitivity of different neuronal populations to the
apoptogenic effects of NMDA antagonists and GABAmimetic
agents, which is highly dependent upon age of exposure. For
example, the hippocampus, subiculum, and caudate/putamen are
more sensitive during the early periods of synaptogenesis, while
other areas, particularly cortical regions and some thalamic nuclei
tend to be sensitive in mid to later periods [5]. To date, reports on
the long-term behavioral effects of postnatal PCP exposure have
focused on P7 or later, which corresponds to the mid to late period
of synaptogenesis. Thus, another goal of our research was to
determine if exposure to PCP on P2 in mice results in a different
pattern of cognitive and behavioral disturbances than those
resulting from exposure on P7. In addition, since the developing
human brain may be subjected to multiple PCP exposures during
synaptogenesis, we also studied the potential long-term functional
deficits of mice exposed to PCP during the two periods of
vulnerability (P2 and P7).
Methods
Ethics Statement
All experimental protocols were approved by the Animal
Studies Committee of Washington University in St. Louis in
accordance with NIH guidelines.
Animals
C57BL/6 mice, purchased from Harlan (Indianapolis, IN), were
used and given free access to food and water while maintained on a
12 hr on/off light-dark schedule in a temperature- and humidity-
controlled room throughout the experiments. Pregnant dams were
individually housed in polypropylene cages measuring 30618.56
13 cm, while offspring were weaned on P21 and group-housed with 5
same-sexed cagemates.Weights and general appearance of the animals
were carefully monitored throughout the experiments.
Pharmacological Agents and Drug Treatments
Phencyclidine (PCP) (Sigma Laboratories, St. Louis, MO) was
solubilized in sterile saline diluents for subcutaneous injection
according to body weight (10ml/g). Doses used on P2 (35 mg/kg)
and P7 (50 mg/kg) were based on results from pilot studies
showing that these were doses that produce a robust neuroapop-
totic response without causing high levels of mortality at these
ages. Animals were randomly assigned to one of six treatment
groups: 35 mg/kg PCP on P2; 50 mg/kg PCP on P7; or 35 mg/
kg on P2 followed by 50 mg/kg on P7, or matched saline controls.
For the histological studies, each of the six groups included 6
animals from 6 different litters to control for litter effects (N=36).
Histological Procedures
Immunocytochemical techniques were used to detect neuroapop-
tosis through activated caspase-3 (AC3) staining as previously
described [12]. Specifically, 10 hr after drug exposure for a given
PCP or saline control treatment, mice were deeply anesthetized with
sodium pentobarbital and perfused with a heparinized saline flush
followed by 4% paraformaldehyde in a 0.1 M sodium phosphate
buffer. Immediately following perfusion, the whole brain was
removed from each animal and post-fixed in perfusate for 4 d.
Whole brains were cut into 70 mm sections on a Vibratome and
stored in phosphate buffered saline (PBS). Sections were washed in
0.01 M PBS, quenched for 10 min in methanol containing 3%
hydrogen peroxide, and then incubated for 1 hr in blocking solution
(2% BSA/0.2% milk/0.1% Triton-X 100 in PBS), followed by
incubation overnight in rabbit anti-active caspase-3 antiserum (Cell
Signaling Technology, Beverly, MA). Sections were incubated for
1 hr in secondary antiserum (goat anti-rabbit 1:200 in blocking
solution), and then reacted in the dark with ABC reagents (standard
Vectastain ABC Elite Kit; Vector Laboratories, Burlingame, CA) for
1 hr. The sections were then washed 3 times with PBS, and incubated
with VIP reagent (Vector VIP substrate kit for peroxidase, Vector
Labs, Burlingame, CA). To quantify differences in neuroapoptosis
between P7 and P2+P7 treatments, three coronal sections were
selected from each animal, one including the caudate and anterior
cingulate cortex (P6#18, 3.51 mm), laterodorsal thalamic nuclei (P6
# 27, 4.59 mm) and retrosplenial cortex (P6 #33, 5.31 mm), [13].
Caspase-postive neurons in the cortex, caudate, and thalamus were
counted using StereoInvestigator 7 (MicroBrightfield, Inc., Williston,
VT) and a mean density score was derived for each animal.
General Design of Behavioral Experiments
In the first behavioral experiment, a total of 32 mice were used
from 5 litters. One male and one female pup from each litter
received an injection of 50 mg/kg of PCP on P7. Litter-matched
controls received saline injections. All pups were placed in a warm
(30u) environment resembling the home nest until the effects of the
drug appeared to dissipate (10 hr), and then returned to their
respective dams. In two subsequent experiments mice were
exposed to PCP or saline on P2 (N= 60) or P2+P7 (N= 60). Both
genders were represented in each group, and litter-matching
techniques were used to assign groups. A second saline control
group was included in these experiments to assess the effects of
maternal deprivation alone at these time points. Pups from each
litter were therefore assigned to one of 3 groups (PCP, saline, or
saline+maternal deprivation) such that no treatment or control
condition was repeated within the same litter. Mice exposed to
PCP or saline in all three experiments (P2, P7, and P2+P7) were
evaluated behaviorally during the juvenile period and into
adulthood on the following measures: (1) on P23-24, 1 hr
locomotor activity and a battery of sensorimotor tests (walking
initiation, ledge, inclined and inverted screens and pole, described
in further detail in [7]); (2) the Morris water navigation test to
evaluate spatial learning and memory at P28, P75, and P170; (3)
acoustic startle and pre-pulse inhibition at P50; and (4) Pavlovian
fear conditioning on P60.
Spatial Learning and Memory
Spatial learning and memory were evaluated in the mice using
the Morris water navigation test which involved training mice to
locate a platform in a pool of opaque water using methods similar
to those previously described [7]. The procedure included cued
trials (visible platform, varied location, 4 trials/day, 2 days)
conducted on P28–29, followed by place trials (submerged
platform, fixed location, 2 trials/day, 10 days) beginning on P30.
Release points each day were pseudorandomly determined across
the four pool quadrants such that each release point was used
equally. Probe trials (platform removed) were conducted 1 hr after
the last place trial on days 5 and 10. Mice were re-evaluated on the
place condition on P75 (62 days) using the same procedures
except that a different submerged platform location was used in
the presence of different extramaze cues. Probe trials on days 5
and 10 of place training were also different in that mice received a
30 s probe before testing on day 5 or 10 (24 hr delay) and a 30 s
probe after place training on those days (1 hr delay). Mice in the
P2+P7 experiment were also tested on cued, place and probe
conditions on P170 using a different submerged platform location
and different extramaze cues.
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Acoustic Startle Response (ASR) and Pre-Pulse Inhibition
(PPI)
The ASR to a 120 dBA auditory stimulus pulse (40 ms
broadband burst) and PPI (response to a prepulse plus the startle
pulse) were measured concurrently in the mice on P50 using
previously described methods [14,15]. Beginning at stimulus onset,
65, 1 ms force readings were averaged to obtain an animal’s startle
amplitude. A total of 20 startle trials were presented over a 20 min
test period during which the first 5 min served as an acclimation
period when no stimuli above the 65 dB white noise background
were presented. The session began and ended by presenting 5
consecutive startle (120 db pulse alone) trials unaccompanied by
other trial types. The middle 10 startle trials were interspersed with
PPI trials (consisting of an additional 30 presentations of 120 dB
startle stimuli preceded by pre-pulse stimuli of either 4, 12, or 20
dB above background (10 trials for each PPI trial type). A percent
PPI score for each trial was calculated using the following
equation: %PPI= 100*(ASRstartle pulse alone - ASRprepulse+
startle pulse)/ASRstartle pulse alone (see [14] for greater details).
Conditioned Fear
A previously described protocol [16] was used to train and test
mice using two clear-plastic conditioning chambers (26618618 cm
high) (Med-Associates, St. Albans, VT) which were easily
distinguished by different olfactory, visual, and tactile cues present
in each chamber. On day 1, each mouse was placed into the
conditioning chamber for 5 min and freezing behavior was
quantified during a 2 min baseline period. Freezing (no movement
except that associated with respiration) was quantified using
FreezeFrame image analysis software (Actimetrics, Evanston, IL)
which allows for simultaneous visualization of behavior while
adjusting for a ‘‘freezing threshold’’ during 0.75 s intervals. After
baseline measurements, a conditioned stimulus (CS) consisting of an
80 dB tone (white noise) was presented for 20 sec followed by an
unconditioned stimulus (US) consisting of a 1 s, 1.0 mA continuous
foot shock. This tone-shock (T/S) pairing was repeated each minute
over the next 2 min, and freezing was quantified after each of the
three tone-shock pairings. Twenty-four hours after training, each
mouse was placed back into the original conditioning chamber to
test for fear conditioning to the contextual cues in the chamber. This
involved quantifying freezing over an 8 min period without the tone
or shock being present. Twenty-four hours later, the mice were
evaluated on the auditory cue component of the conditioned fear
procedure, which included placing each mouse into the other
chamber containing distinctly different cues. Freezing was quanti-
fied during a 2 min ‘‘altered context’’ baseline period as well as over
a subsequent 8 min period during which the auditory cue (CS) was
presented. Shock sensitivity was evaluated following completion of
the conditioned fear test as previously described [17].
Statistical Analyses
In general, analysis of variance (ANOVA) models were used to
evaluate the data. Most behavioral data were analyzed using a
repeated measures factorial model containing two between-
subjects variables (Group and Gender), and one within-subjects
variable (e.g., Blocks of Trials). The Huynh-Feldt (H-F) adjustment
of alpha levels was used for all within-subjects effects containing
more than two levels in order to protect against violations of the
sphericity/compound symmetry assumptions underlying the
repeated measures ANOVA model. Pairwise comparisons (Bon-
ferroni corrected significance levels) were conducted after
significant main effects of Group or significant interactions
involving Group across time variables like Blocks of Trials.
Results
Neurodegenerative Effects of PCP
Evaluation of coronal sections stained by AC3-immunohisto-
chemistry revealed that all brains exposed to PCP either at P2, P7
or P2 + P7 had substantially larger numbers of stained profiles in
many different regions than were present in the saline control
brains. Consistent with a prior report in rats pertaining to
neuroapoptosis induced by NMDA antagonists [1], there were
some similarities but also major differences in the pattern of
neuroapoptosis that occurred following PCP exposure on P2
compared to that observed following exposure on P7. Notable
similarities involved dense staining of AC-3 positive profiles in the
anterior and laterodorsal nuclei of the thalamus and the caudate/
putamen following PCP exposure at both ages. The most
prominent differences included a high density of stained profiles
in the hippocampus and certain subcortical structures such as the
hypothalamus and amygdala, but very few stained profiles in the
neocortex in mice exposed to PCP on P2. In contrast, all divisions
of the neocortex showed a high density of staining in mice exposed
to PCP on P7 with the hippocampus, hypothalamus and amygdala
being less prominently affected (Fig. 1). On the basis of qualitative
comparisons, it appeared, in general, that there were more densely
stained AC3-positive profiles in the P2+P7 PCP-treated brains
compared to that observed in the P7 alone PCP group. This was
confirmed by quantitative counts of stained AC3-positive profiles
that were summed across three representative regions that
appeared to contain the greatest density of staining (retrosplenial
cortex, caudate putamen, anterior thalamic nuclei). Statistical
analysis of the quantitative counts demonstrated that the density of
AC3-positive profiles was significantly different among the
treatment groups [F(2,14) = 34.92, p,0.0001], with subsequent
pairwise comparisons showing that the density of profiles was
significantly greater in the P2+P7 PCP-treated group compared to
levels observed in the P7 PCP-treated mice (p= 0.012). Also, each
of the two PCP-treated groups showed significantly greater
staining density compared to the saline group (p,0.002) (Fig. 2).
Effects of PCP on Body Weight
Animals treated with a single dose of PCP on P2 weighed
significantly less than either normal (suckle) (p = 0.009) or deprived
controls (p = 0.00001) across postnatal days P2-P14. Overall
ANOVA indicated significant differences among groups at P21
[F(2,57) 3.326, p = 0.043], however differences between groups
were not significant in post-hoc analysis and by P45 no significant
difference were observed among groups. Exposure to a single dose
of PCP on P7 also resulted in decreased body weights across
postnatal days P7–14 compared to deprived controls (p = 0.00009)
and at P21 [F(1,28) = 11.974, p = 0.0017). Body weight analysis at
P45 revealed no significant differences between groups. An
analysis of body weights from the P2+P7 PCP experiment showed
that across postnatal days P2–P14, the PCP-treated mice weighed
significantly less than either the normal (suckle) or deprived control
groups (p,0.0005) (Fig. 3A). In addition, the deprived mice also
weighed significantly less than normal controls (p = 0.004) across
these postnatal days suggesting that at least some of the decreases
in body weights in the PCP-treated mice resulted from the time the
pups were denied access to the dam. Analysis of body weights at
weaning (P21) showed the same pattern of significant results
(Fig. 3B). Although there were relatively long-term differences in
absolute body weights, an analysis of body weight changes over the
P2–P14 period showed that significant losses of body weight in the
PCP-treated mice were restricted to the first post-treatment day
(data not shown). Moreover, the PCP-treated mice rebounded
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quickly and actually showed greater body weight gains than either
control group by P9–10, an effect that remained until P17–18 (not
shown). In spite of the differences in absolute body weights, no
obvious developmental abnormalities or differences in general
health were observed among the three groups. Analysis of absolute
body weights measured at (P60) showed no significant differences
among PCP-treated animals and controls (Fig. 3C).
Behavioral Effects of PCP Exposure on P2
Preliminary analyses were conducted between the normal and
deprived controls with regard to the data from the cued, place and
probe conditions in the water maze and from the conditioned fear
task, with the result being that no differences were observed
between the two groups on any of the learning and memory
measures. As a result, the data from the two groups were
combined and ANOVAs were conducted on the P2 PCP-treated
mice and the combined control group in an effort to clarify the
effects of PCP treatment on learning and memory.
Animals exposed to PCP on P2 did not differ from controls on
measures of locomotor activity, sensorimotor function, water maze
acquisition at P30, or of the ASR/PPI, contextual fear or auditory
cue tests, or on water maze acquisition and retention measured at
P75 (data not shown). However, they did show mild retention
impairments in water maze testing at P30 as indicated by a
decreased number of platform crossings compared to control
groups during the first probe trial [F(1,58) = 9.99, p = 0.002]; this
difference was no longer significant by the second probe trial
conducted at the end of place training (data not shown).
Behavioral Effects of PCP Exposure on P7
Animals exposed to PCP on P7 did not differ from controls
on measures of locomotor activity, sensorimotor function,
water maze acquisition or retention at P30 or P75, or of the
ASR/PPI. No significant differences between groups were
observed on the contextual fear test, or on a test of shock
sensitivity. However, mice exposed to PCP on P7 exhibited
significantly less freezing in response to the tone during the
auditory cue test compared to saline controls [F(1,28) = 4.43,
p = 0.02] (data not shown).
Behavioral Effects of PCP Exposure on P2+P7
Analyses of the normal and deprived control groups again
showed no significant differences on any learning and memory
measures at any age (P30, P75, P170) so the data from the two
groups were combined for statistical analyses conducted on the
P2+P7 PCP-treated mice in an effort to simplify the
interpretation of the effect of PCP treatment on learning and
memory.
Similar to the results from the studies involving PCP treatment
on P2 or on P7, there were no significant differences between
groups on the early post-weaning 1 hr locomotor activity test
including indices of altered emotionality, or on any of the
measures from the sensorimotor battery (data not shown).
Likewise, there were no significant overall effects observed on
any of the variables from ASR/PPI testing conducted on P50 (data
not shown).
Figure 1. Pattern of neuroapoptosis following PCP treatment in neonatal mice differs depending on whether exposure occurs on
P2 or P7. Photomicrographs showing activated caspase3- (AC3-) positive cell profiles indicating neuroapoptotic damage in the retrosplenial cortex
(RSC), hippocampus (HIP), OR anterodorsal thalamic nuclei (THAL) in mice that were treated with PCP on either P2 (P2PCP) or P7 (P7PCP) or with
saline on the same postnatal days (P2 Saline and P7 Saline, respectively). PCP exposure on P2 produced neuroapoptotic damage to the HIP and THAL
regions without affecting the RSC. In contrast, PCP exposure on P7 resulted in severe neuroapoptosis in the RSC and moderate damage to the THAL,
while leaving the HIP relatively spared. Images taken at 106magnification.
doi:10.1371/journal.pone.0011374.g001
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PCP Exposure on P2+P7 Produces Severe Spatial
Learning and Memory Impairments at P30
A significant main effect of Group, [F(1,56) = 6.30, p= 0.015],
and a significant Group by Gender by Blocks of Trials 3-way
interaction [F(3,168) = 3.60, p = 0.017], suggested that group
performances with regard to path length differed over the blocks
of cued trials (Fig. 4A) although differential gender effects may
have occurred within treatment groups. Importantly, PCP-treated
mice did not differ significantly from control mice on any single
block of trials suggesting minimal (if any) performance differences
between groups. Other contrasts comparing male PCP-treated
mice with male controls and female PCP-treated mice with female
controls did not produce significant performance differences
between the groups, on average across the blocks of trials,
suggesting that there were no meaningful effects of PCP treatment
as a function of Gender. Clearly, by the last block of cued trials,
virtually identical performance levels were observed in the two
groups (Fig. 4A). Similar, although slightly larger, overall effects
were observed for escape latency (data not shown). An ANOVA of
swimming speeds over trials did not yield any significant effects
involving Group or Gender (data not shown). In summary, small
differences may have existed between P2+P7 PCP-treated and
control mice during the cued trials resulting in transient
performance deficits suggesting that mild non-associative distur-
bances in the PCP-treated mice (e.g., visual or sensorimotor
disturbances, altered motivation) may have briefly affected
performance although the two groups eventually performed at
approximately equal levels.
In contrast to the small effects of P2+P7 PCP treatment on cued
trials performance, PCP-treated animals showed robust and
significant acquisition deficits during the place condition of the
water maze at P30 (Fig. 4B), [Group main effect: F (1,56) = 19.03,
p,0.0005], but no other overall effects involving Group or
Gender were significant. Subsequent pairwise comparisons
showed that differences between PCP-treated and controls were
significant beyond Bonferroni correction (p = 0.05/5= 0.01) for
blocks 1, 2, and 3 (p,0.009), while differences were also large for
blocks 4 (p= 0.042) and 5 (p = 0.011). The same effects were
observed in the analysis of the latency data but were generally
greater in magnitude (data not shown). An ANOVA of the
swimming speed data (Fig. 4C) showed a significant main effect of
Group, [F(1,56) = 4.91, p = 0.031], and a significant Gender by
Group interaction, [F(1,56) = 11.64, p= 0.001]. However, subse-
Figure 3. PCP treatment on P2 and P7 (P2+P7) significantly reduces body weights relative to both normal and deprived controls
during the early pre-weaning period. (A) An ANOVA on body weights yielded a significant main effect of Group, [F(2,57) = 139.17, p,0.0005],
and a significant Group by Postnatal Day interaction, [F(24,684) = 76.07, p,0.000], showing that there were different patterns of body weights in the
three groups across P2-P14. Groups differed significantly (*p,0.0005) on each postnatal day except P2. Across postnatal days, the PCP-treated mice
weighed significantly less than either the normal (a`a`p,0.0005) or deprived (a`p,0.0005) control groups, and the deprived mice also weighed
significantly less than normal controls (a`a`a`p = 0.005). (B) The groups also differed significantly in body weights at weaning (P21), (*p,0.0005), and
pairwise comparisons indicated that the PCP-treated mice weighed less than either the normal or deprived controls (*, **p,0.0005), and the deprived
group weighed less than the normal controls ( p = 0.013). (C) Analysis of absolute body weights at P60 indicated no significant differences. P2 and P7
PCP single treatment groups are included for general comparison.
doi:10.1371/journal.pone.0011374.g003
Figure 2. Density of AC3-positive profiles is greater when PCP
exposure occurs on P2 and P7 (P2+P7) compared to exposure
on P7 alone. Density of AC3-positive cell profiles summed across
forebrain regions most sensitive to PCP-induced neuroapoptosis on P7
(retrosplenial cortex, caudate putamen, anterior thalamic nuclei) is
significantly (**p=0.012) greater in mice that were exposed to PCP on
P2 and P7 (P2+P7PCP group) compared to that observed in mice that
were treated only on P7 (P7PCP). The P7PCP and P2+P7PCP groups
each showed significantly greater densities of AC3-positive profiles
compared to the saline controls ({p=0.001; *p,0.00005, respectively).
Numbers in parentheses indicate sample sizes of each group.
doi:10.1371/journal.pone.0011374.g002
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Figure 4. P2+P7 PCP treatment impairs spatial learning and memory in the Morris water maze. (A) An effect of Group (**p = 0.015) and a
Group by Gender by Blocks of Trials interaction (***p = 0.017), suggested group differences in path length over trials in the cued condition. However,
PCP-treated mice did not differ significantly from control mice on any single block of trials suggesting differences were minimal, and additional
contrasts did not indicate meaningful gender effects. (B) PCP-treated animals showed significant acquisition deficits at P30 (**p,0.0005) for blocks 1,
2, and 3, (*p,0.009) while large differences were found for blocks 4 ({p=0.042) and 5 ({p= 0.011). (C) Swimming speeds of PCP-treated mice were
slower than controls during place trials (**p= 0.031), although pairwise comparisons showed no significant difference in any given block of trials. (D)
Behavioral Effect of Apoptosis
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quent pairwise comparisons showed no significant differences
beyond Bonferroni correction (p = 0.01) between PCP-treated and
control mice for any given block of trials. Additional contrasts
indicated that the Gender by Group interaction effect was mostly
due to the PCP-treated males swimming significantly slower, on
average across trials, compared to the control male mice
(p,0.0005), while no differences were observed between the two
groups of females (data not shown). Analysis of the data from the
first probe trial conducted midway through acquisition (day 5)
showed no evidence of spatial bias in either group for the target
quadrant and no differences were observed in platform crossings.
An ANOVA of the platform crossing data from the second probe
trial (day 10), revealed a significant Gender by Group interaction
in platform crossings [F (1,56) = 7.08, p = 0.010], but no other
overall effects including Group. However, the lack of significant
performance differences following comparisons conducted be-
tween the two male groups and between the two female groups
suggested that there were no meaningful gender-based effects of
PCP treatment. The control mice exhibited good retention of the
platform location by the second probe trial at the end of training
(day 10) when they showed a significant spatial bias for the target
quadrant where their search times were significantly greater than
those observed in each of the other quadrants (p,0.0005), while
the PCP-treated mice showed no such bias for the target quadrant
(Fig. 4D).
P2+P7 PCP2 treated mice are still impaired on the water
maze task during retesting at P75 but show signs of
recovery
Retesting the mice on a new hidden platform location at P75
indicated a general reduction in performance differences between
the two groups suggesting partial recovery of function on the part of
the PCP-treated mice (Fig. 4E). Nevertheless, significant main
effect of Group, [F (1,56) = 7.69, p= 0.008], showed that, in general,
the path lengths of the PCP-treated mice were significantly longer
than those of the control group during acquisition of the new
platform location. Subsequent comparisons indicated that differ-
ences between the groups were greatest for blocks 3 (p= 0.049), and
5 (p= 0.033]. The same pattern of overall effects was found for the
latency data (not shown). The ANOVA on the swimming speed
data showed a significant Group by Gender interaction,
[F(1,56) = 4.84, p= 0.032], although subsequent pairwise compar-
isons showed no differences between PCP-treated and control males
or between PCP-treated and control females indicating that this
effect had little meaning with regard to the effect of PCP treatment.
Probe trial performance midway through acquisition training (day
5) indicated no significant differences between the groups in terms of
platform crossings or spatial bias for the target quadrant during the
24 hr delayed probe. However, although no differences between
groups were found for platform crossings in the 1 hr delay probe
trial on day 5, the control mice exhibited a significant spatial bias for
the target quadrant, (p,0.007 for target vs each of the other
quadrants), while the PCP-treated group did not (Fig. 4F).
Regarding probe trial performance at the end of acquisition (day
10), no significant differences were observed between the two groups
for either probe trial in terms of platform crossings, and both groups
showed significant spatial bias for the target quadrant (data not
shown). In summary, the results from the water maze testing at P75
indicated that the PCP-treated mice still had subtle deficits relative
to the control mice during acquisition and retention of the new
platform location.
P2+P7 PCP-treated mice showed robust deficits when
retested on the water maze task at P170 in the absence
of continued handling and testing
In order to determine whether the apparent recovery of
function in PCP-treated mice continued beyond water maze
testing at P75, the mice were left unhandled except for cage and
bedding changes for 70 days beginning around P100 and then
were re-tested at P170. We were particularly interested in
determining whether the spatial learning capabilities of the PCP-
treated mice would become normalized during testing at a later
age. Because of the slight differences observed in cued trial
performance at P30, we decided to conduct the cued trials again to
determine if any deficits were still demonstrable in the PCP-treated
mice. Analysis of the path length data from cued trials testing at
P170 provided some weak evidence that the performance of the
PCP-treated mice may have been subtly impaired during the cued
condition (Fig. 4G). For example, a significant Group by Blocks
interaction [F(3,168) = 4.08, p = 0.010] was found suggesting
different patterns of group performances occurred across blocks
of trials. However subsequent pairwise comparisons showed that
the greatest differences in path lengths between groups were found
during the first block of trials (p = 0.023), although this difference
was not significant following Bonferroni correction (p = 0.0125).
The same pattern of results was found for the latency data (not
shown). An ANOVA of the swimming speed data yielded a
significant main effect of Gender, [F(1,56) = 31.04, p,0.0005], a
significant Group by Gender interaction, [F(1,56) = 20.37,
p,0.0005], and a significant Group by Blocks interaction,
[F(3,168) = 2.90, p = 0.036]. Subsequent contrasts showed that
these effects were at least partially due to the PCP-treated males
being significantly slower swimmers than the PCP-treated females,
on average across the blocks of trials (p,0.0005), whereas no
gender differences were observed with regard to swimming speeds
for the control mice (data not shown). Importantly, however,
differences in swimming speeds were not associated with
differences in cued learning performance since no gender-based
effects were found on these variables. Thus, the cued data from
this adult water maze testing was similar to that observed during
the earlier testing when the mice were juveniles in that a small,
transient impairment may have been present in the PCP-treated
mice but only during the initial phase of testing.
Analysis of the P170 place trials data indicated that the PCP-
treated mice did not show evidence of continued improvement in
spatial learning performance suggesting that further recovery of
function did not proceed into later adulthood. Instead, the PCP-
treated mice displayed large and significant acquisition deficits
during the place condition relative to the control mice that were
greater than those observed during the P75 place trials [Group
Control mice showed good retention at the end of training (**p,0.0005). Specifically, they showed spatial bias for the target quadrant (*p,0.0005).
(E) PCP-treated mice showed acquisition deficits at P75 (**p= 0.008). Differences were greatest for blocks 3 ({p=0.049), and 5 ({p= 0.033). (F) For the
1-h delay probe trial control mice exhibited spatial bias for the target quadrant, (**p,0.0005; *p,0.007 for target vs each of the other quadrants) (G)
A Group by Blocks interaction (**p = 0.010) was observed for the cued trials at P170. Greatest differences occurred during the first block ({p=0.023,
not significant past Bonferroni correction p= 0.0125). (H) PCP-treated mice displayed acquisition deficits at P170 (**p = 0.003), specifically for blocks 1,
2, and 3 (*p,0.007) and for block 4 ({p=0.018). (I) During the first 24-h delay probe trial control mice showed spatial bias for the target quadrant
(**p,0.0005; *p,0.0005 for target vs each of the other quadrants), while PCP-treated mice did not.
doi:10.1371/journal.pone.0011374.g004
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effect: [F (1,56) = 16.77, p,0.0005; Group by Blocks interaction: F
(4,224) = 4.41, p= 0.003] (Fig. 4H). Subsequent pairwise compar-
isons showed that PCP-treated mice had significantly longer path
lengths compared to the control group for blocks 1, 2, and 3
(p,0.007), while differences were also very large for block 4
(p= 0.018). Similar results were found for the latency data (not
shown). An ANOVA of the swimming speed data revealed a Group
by Blocks interaction, [F(2,224) = 4.71, p= 0.023], and a Gender by
Blocks interaction, [F(4,224)= 5.86, p= 0.010]. Pairwise compari-
sons showed that the PCP-treated mice had significantly slower
swimming speeds compared to controls only during blocks 1 and 2
(p= 0.01). Additional contrasts showed that, similar to the cued
trials data, PCP-treated males swam significantly slower than PCP-
treated females during blocks 1 through 3 (p,0.0004) while no
differences were observed between the male and female control
mice (data not shown). Analysis of the probe trial data showed that
the PCP-treated mice exhibited inferior retention performance
compared to the control group. Specifically, the PCP-treated mice
made significantly fewer platform crossings during the first, 24 hr
delayed probe trial (p= 0.047) relative to the controls and they never
showed significant spatial bias for the target quadrant during any of
the four probe trials. In contrast, the control mice showed significant
spatial bias for the target quadrant during the first (Fig. 4I) and
second 24 hr delay probe trials (p,0.0006), but not for either of the
1 hr delay probes. Collectively, the water maze experiments show
that the P2+P7 PCP treatment produces long-term, probably
permanent, spatial learning and memory impairments although the
degree of performance deficits may depend upon stimulation
resulting from handling and exposure to other behavioral measures.
P2+P7 PCP2treated mice showed significant
impairments in conditioned fear
The mice were also evaluated on Pavlovian fear conditioning on
P60, between the first two water maze tests, to determine whether
the P2+P7 PCP-treatment affected other non-spatial forms of
learning. Analysis of freezing behavior during the baseline or
tone/shock pairings on day 1 revealed no significant effects
(Fig. 5A) indicating that the two groups exhibited similar levels of
baseline freezing upon being introduced to the conditioning
chamber and in response to the tone-shock training (CS-US
pairings). However, the PCP-treated mice exhibited significantly
lower amounts of freezing compared to the control group,
[F(1,56) = 14.30, p,0.0005], when they were returned to the test
chamber 24 hr after training to evaluate contextual fear
conditioning (Fig. 5B). The PCP-treated mice froze significantly
less often than the controls in response to the contextual cues for
each of the first 4 min of the test session (p,0.0006) while
differences were also substantial for min 5 (p= 0.040) and 6
(p = 0.025). An analysis of baseline freezing in response to the
altered context on day 3 indicated a significant Group by Minutes
interaction [F(1,56) = 13.22, p= 0.001], which was mostly due to
significant differences between the PCP-treated and control mice
during minute 2 (p = 0.001), when the PCP-treated mice exhibited
significantly less freezing. Analysis of freezing in response to the
tone presentation yielded a significant main effect of Group,
[F(1,56) = 14.21, p,0.0005], and a significant Group by Minutes
interaction, [F(7,392) = 2.19, p= 0.048] showing that the PCP-
treated mice froze less than the controls but the magnitude of the
differences was time dependent. Specifically, the PCP-treated mice
froze significantly less often than the control group for minutes 1,
2, and 8 (p,0.006), while very large differences were also observed
for minutes 6, 7, and 9 (p,0.025) (Fig. 5C). However, since we
did not include additional control groups for the auditory cue
condition, we cannot determine whether impaired performance on
this task represents deficits in actual conditioning or in other
behavioral processes such as sensitization. Thus, in summary, the
PCP-treated group showed impaired contextual fear conditioning
and performance deficits during the auditory cue test relative to
Figure 5. P2+P7 PCP-treated mice showed significant impairments in conditioned fear when tested on P60. (A) Analysis of freezing
behavior during the baseline or tone/shock (T/S) pairings on day 1 revealed no significant overall Group effects. (B) PCP-treated mice exhibited
significantly lower amounts of freezing compared to the control group when they were returned to the test chamber 24 hrs after training
(**p,0.0005). Pairwise comparisons showed that the PCP-treated mice froze significantly less often than controls in response to contextual cues for
the first 4 min of the test session (*p,0.0006) while differences were also large for min 5 ({p= 0.040) and 6 ({p= 0.025). (C) An analysis of baseline
freezing in response to the altered context on day 3 of auditory cue testing indicated a significant Group by Minutes interaction (**p = 0.001).
Subsequent pairwise comparisons showed that this effect was mostly due to differences between the PCP-treated and control mice during min 2
(*p = 0.001). Analysis of freezing in response to the tone presentation yielded a significant main effect of Group (**p,0.0005) and Group by Minutes
interaction (***p= 0.048) with pairwise comparisons showing that the PCP-treated mice froze less often than the control group for min 1, 2, and 8
(*p,0.006), while very large differences were also observed for min 6, 7, and 9 ({p,0.025).
doi:10.1371/journal.pone.0011374.g005
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the control mice, although differences in baseline freezing in
response to the altered context may have contributed to the latter
effect.
Discussion
Our findings indicate that exposing mice to PCP on two
postnatal days (P2+P7) results in severe, long-term impairment in
spatial learning and memory, and in contextual fear conditioning,
whereas mouse pups exposed to PCP on only a single postnatal
day (either P2 or P7) sustained only minor behavioral disturbanc-
es. The P2+P7 group was subjected to Morris water maze testing
at 3 ages (P30, P75, P170). Between the P30 and P75 testing, the
mice were extensively handled and subjected to frequent
behavioral testing, but between P75 and P170 handling was
intentionally kept to a minimum. The learning/memory deficits,
which were very severe at P30, remained quite severe at P170, but
were less severe at P75. We propose that the improved test
performance at P75 reflects the frequency of handling and
repeated testing in the interval between P30 and P75, and the
poor performance at P170 confirms the permanency and severity
of neurocognitive impairments resulting from P2+P7 PCP
exposure in infancy. In a prior study we reported that exposure
of infant mice to alcohol caused severe learning/memory deficits
at P30 followed by an apparent partial recovery of function when
tested at P75. The present results suggest that frequent stimulation
and familiarity of continued behavioral testing provides some
remediation in mice treated with either alcohol or PCP in infancy,
but it may not lead to genuine neural repair or complete recovery
of cognitive function.
Our findings support and extend prior work by Wang et al.,
[8,9], who reported that exposing female rat pups to PCP on three
postnatal days (P7+P9+P11) slowed acquisition of a delayed spatial
alternation task when testing began on P42. In the present study
we have demonstrated that robust spatial learning and memory
deficits occur in mice that were subjected to two PCP exposures
(i.e., on P2+P7) but not as a result of a single exposure on P2 or P7,
and that these impairments are likely to be permanent in nature
and encompass non-spatial forms of learning as well. In addition,
Wang and colleagues focused on the effects of PCP exposure that
occurred later during the developmental period of synaptogenesis
(P7, 9 and 11) while our study examined the effects of PCP-
induced neuroapoptosis at earlier ages (P2 and 7) to determine the
different patterns of neuroapoptosis that occur following single or
double dosing regimens during this time.
Our findings confirm earlier observations that the pattern of
neurodegeneration induced in the developing brain by an
NMDA antagonist drug varies depending on the age at time of
exposure [5,18]. PCP exposure on P2 caused prominent AC3
staining in the hippocampus and certain subcortical regions (e.g.,
hypothalamus and amygdala), but very limited staining in
neocortex. In contrast, PCP exposure on P7 resulted in dense
AC3 staining in all divisions of the neocortex, while staining in
the hippocampus, hypothalamus and amygdala was much less
prominent. Dense AC3 staining was found in the anterior and
laterodorsal nuclei of the thalamus and the caudate/putamen
following PCP exposure on each of these postnatal days. Neither
the P2 nor P7 pattern was associated with severe learning and
memory impairment, but the P2+P7 pattern was. Quantitative
counts on P7 assessing the density of AC3-positive profiles in
three severely affected brain regions (retrosplenial cortex,
caudate/putamen, anterior thalamic nuclei) revealed that the
damage was more severe in mice treated with PCP on P2+P7
than those treated only on P7. Because cells dying by apoptosis
are no longer AC3 positive approximately 24 hours after drug
exposure, the increased AC3 staining in the P2+P7 animals
compared to the P7 animals cannot be reflective of damage that
is still visible from the P2 exposure. Rather the increased staining
in the P2+P7 animals indicates that PCP exposure at P2 has
produced alterations in the brain that result in it being more
susceptible to the apoptotic effects of PCP at P7.
Traditionally, spatial learning and memory deficits have been
linked to hippocampal dysfunction. However, there is substantial
evidence that an extended extra-hippocampal circuit plays a role
in mediating allocentric (landmark-based) spatial learning and
memory functions such as those evaluated in rodents with the
water navigation task [19,20]. This circuit includes, in addition to
the hippocampal formation, the retrosplenial cortex, anterior
thalamic nuclei and mammillary bodies [19]. In the P2+P7 group
all of these regions were involved except for the mammillary
bodies. In a prior study [7] we showed that alcohol damages all of
these regions, including the mammillary bodies, but the latter
occurs on a delayed basis (16–24 hrs) and would not have been
detected in the present study (histological evaluation at 10 hrs). In
addition, neuroapoptosis in the caudate/putamen may amplify
these effects since it has been shown to be involved in incremental
learning involving stimulus-response associations, and there is
evidence implicating the medial dorsal striatum in place learning
in the water maze [21].
Nutritional status may have played a contributory role to the
cognitive deficits observed in the P2+P7 PCP-treated mice,
although the evidence suggests otherwise. For example, transient
weight loss in the period immediately following treatment
occurred in all PCP-treated groups of mice, with absolute body
weights remaining lower than control mice until early adulthood.
However, PCP-treated mice showed normal weight gains within
two days post-treatment suggesting a quick resumption in normal
growth rates in the drug-treated mice. Evidence that nutritional
deficiencies had little or no impact on the behavior of P2+P7 PCP
mice come from several sources. For example, the P2+P7 PCP-
treated mice did not exhibit impaired performance during the 1 h
locomotor activity test, either in terms of general activity or
emotionality variables relative to the control mice. The P2+P7
PCP mice also did not display performance deficits on any of the
measures within the sensorimotor battery or in terms of ASR/PPI
responsivity. In addition, the groups of mice that were subjected to
single exposures of PCP on either P2 or P7 had significantly
decreased body weights for similar periods of time but showed
little or no disturbances in learning and memory performance in
the above-mentioned behavioral tests. Specifically, animals treated
with a single dose of PCP at P7 weighed the same as, if not slightly
less, than P2+P7 PCP treated mice at P21 without showing severe
cognitive impairment. In addition, the deprived control mice
weighed significantly less than the normal suckle control group yet
no differences were found between these two groups on any of the
behavioral measures.
Our finding that exposure of infant mice to PCP on two
occasions causes much more severe neurobehavioral impairments
than PCP exposure on only one occasion, may have relevance in a
public health context. There is mounting evidence that anesthetic
drugs, including the NMDA antagonist, ketamine, trigger
neuroapoptosis in the brains of infant rodents [22–25], and
monkeys [26–28], and there is preliminary evidence potentially
linking anesthesia exposure in infancy with long-term neurobe-
havioral deficits in humans [29–31]. In one recent human study
[30] it was found that the risk of neurobehavioral disturbances was
significantly increased if the duration of anesthesia exposure was
greater than 120 minutes or if anesthesia exposure occurred more
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than one time. This is consistent with our finding in infant mice
that PCP, a dissociative anesthetic with NMDA antagonist
properties, causes much more severe neurobehavioral impair-
ments if exposure occurs on more than one occasion.
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